RxDoctor Payments Data

Pamela Pritchard, NP

Acute Care · Fairmont, WVNPI 1912398843

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $147 and has fallen 75.0% since, to $37 in 2025. That places this record below the midpoint for acute care clinicians in WV, where the typical reported total is $273.

$271in general payments, 2019–2025

Across 16 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$56
  • AbbVie$43
  • Lemaitre Vascular, Inc.$28
  • Paratek Pharmaceuticals, Inc.$28
  • Takeda Pharmaceuticals U.S.A., Inc.$24
  • Verona Pharma, Inc.$22
  • plus $70 from 5 others

What the payments were for

  • Food & beverage$271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$271 in reported general payments places this provider in the 45th percentile of 51 acute care providers in West Virginia.

See all acute care providers in West Virginia

Medicare billing

Part B allowed, 2024
$48,682
Medicare patients
64
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$19,149
JanuviaSitagliptin Phosphate15$4,551
ErtapenemErtapenem Sodium11$3,202
LantusInsulin Glargine,hum.Rec.Anlog31$2,262
Potassium Chloride89$941
Pantoprazole Sodium52$936
Atorvastatin Calcium109$925
Levothyroxine Sodium114$913
Metoprolol Succinate72$627
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet13$619
Duloxetine Hcl38$611
Metoprolol Tartrate85$585
Famotidine58$518
ClopidogrelClopidogrel Bisulfate49$480
Carbidopa-LevodopaCarbidopa/Levodopa33$477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$56$4,55115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 51 acute care providers in West Virginia.

Other acute care in Fairmont

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →